News from convergence pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 06, 2014, 02:00 ET Collaboration with Dr Stephen Waxman of Yale University to Evaluate Pharmacology of Nav1.7 Mutations in Chronic Pain Disorders

Agreement follows a very successful preceding collaboration with Dr Waxman with findings due to be presented at IASP 2014 Convergence Pharmaceuticals ...


Sep 23, 2014, 02:58 ET Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy

Highlights of the data: CNV1014802 showed a statistically significant reduction in pain Well tolerated and effective therapeutic dose without any...


Jun 16, 2014, 02:00 ET Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

Convergence Pharmaceuticals ("Convergence" or "the Company") Highlights of the data: CNV1014802 was associated with a consistent reduction of pain...


Jul 08, 2013, 06:27 ET Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Diabetic Peripheral Neuropathy (DPN)

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the...


Apr 23, 2013, 07:32 ET Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the...


Jul 19, 2011, 02:00 ET Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today...


Apr 21, 2011, 09:57 ET Convergence Pharmaceuticals Announces Phase I Trial Start of CNV2197944 for Chronic Pain

- First-time-in-man Study Initiated Ahead of Schedule Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of...